TITLE

Off-label Vistide use associated with serious adverse events

PUB. DATE
February 2011
SOURCE
Reactions Weekly;2/12/2011, Issue 1338, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on a Dear Healthcare Professional letter released by Gilead Sciences which indicated that cidofovir should only be administered to treat cytomegalovirus retinitis in patients with AIDS and no renal dysfunction.
ACCESSION #
58151545

 

Related Articles

  • U. S. FDA Approves Gilead Sciences' Complera(tm), a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naïve Adults.  // Biomedical Market Newsletter;8/12/2011, Vol. 21, p228 

    The article reports that the U.S. Food & Drug Administration (FDA) approved the Compleraâ„¢, an HIV-1 infection drug from Gilead Sciences Inc. It states that Complera tablet is a combination of antiretroviral tablet ripilvirine and Truvada used for the treatment of HIV-1 infection among...

  • GILEAD SUBMITS MAA TO EMEA FOR ADEFOVIR DIPIVOXIL 10 MG.  // Worldwide Biotech;May2002, Vol. 14 Issue 5, p1 

    Reports that Gilead Sciences Inc. has submitted a Marketing Authorisation Application to the European Medicines Evaluation Agency for adefovir dipivoxil drug.

  • P & T PORTFOLIO.  // Drug Topics;1/21/2002, Vol. 146 Issue 2, p12 

    Focuses on tenofovir disoproxil fumarate drug from Gilead. Proprietary name; Pharmacology of the drug; Information on the efficacy of the drug; Adverse effects of the drug.

  • Gilead donates patents for generics. Frantz, Simon // Nature Biotechnology;Oct2011, Vol. 29 Issue 10, p857 

    The article reports on the deal between California-based biotechnology company Gilead Sciences and Geneva, Switzerland-based Medicines Patent Pool (MPP) wherein Gilead will allow generic drug companies to manufacture its human immunodeficiency (HIV) drugs.

  • CAYSTON.  // Nurse Practitioners Prescribing Reference;Summer2010, Vol. 17 Issue 2, pA.9 

    The article offers information on the antibiotic medicine Cayston from Gilead in which it helps improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

  • CAYSTON.  // Physician Assistants' Prescribing Reference;Summer2010, Vol. 17 Issue 2, pA.9 

    The article offers information on Cayston antibiotics with active ingredient aztreonam, which improves respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa, from Gilead Sciences Inc.

  • CAYSTON.  // MPR - Pharmacist's Edition;Summer2010, Vol. 4 Issue 2, pA.8 

    The article provides information on drugs Cayston, an aztreonam antibiotic from Gilead Sciences Inc.

  • Gilead craters. I'm not optimistic.  // In Search of the Perfect Investment;12/22/2014, p1 

    A blog related to Gilead Sciences Inc. (GILD) stock performance is discussed.

  • 'Btripla' Data all the Talk at 2010 IAS Meeting.  // Bioworld Week;7/26/2010, Vol. 18 Issue 30, p3 

    The article reports on the initiatives of California-based Gilead Sciences Inc. to defend its industry-leading HIV franchise against upcoming patent expirations.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics